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The von Willebrand factor (VWF) is a multi-
meric plasma glycoprotein that plays a central
role in hemostasis. VWF acts both as carrier for
coagulation factor VIII in the plasma and as a
mediator of platelet adhesion to subendothelium
after vascular injury. A number of distinct func-
tional domains have been identified within the
VWF, including regions involved in binding to
factor VIII, to platelet receptor GPIb, to platelet
GP IIb-IIIa, to components of extracellular ma-
trix such as collagen and heparin, regions in-
volved in multimerization and dimerization of
VWF, and the A1 and A2 domains involved in the
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Summary: Recessive type 3 von Willebrand disease (VWD) is
caused by homozygosity or double heterozygosity for two non-sense
mutations (null alleles). Type 3 VWD is easy to diagnose by the com-
bination of a strongly prolonged bleeding time (BT), absence of ris-
tocetine-induced platelet aggregation (RIPA), absence of von
Willebrand factor (VWF) protein, and prolonged activated partial
thromboplastin time (aPTT) due to factor VIII:coagulant (FVIII:C)
deficiency. VWD type 3 is associated with a pronounced tendency to
mucocutaneous and musculoskeletal bleedings since early childhood.
Carriers of one null allele are usually asymptomatic at VWF levels of
50% of normal. Recessive severe type 1 VWD is caused by homozy-
gosity or double heterozygosity for a missense mutation. Recessive
type 1 VWD differs from type 3 VWD by the presence of detectable
von Willebrand factor: antigen VWF:Ag and FVIII:C levels between
0.09 and 0.40 U/mL. Patients with recessive type 1 VWD show an ab-
normal VWF multimeric pattern in plasma and/or platelets consis-
tent with severe type 2 VWD. Carriers of a missense mutation may
have mild bleeding and mild VWF deficiency and can be diagnosed
by a double VWF peak on cross immunoelectrophoresis (CIE). There
will be cases of mild and moderate recessive type 1 VWD due to dou-
ble heterozygosity of two missense mutations, or with the combina-
tion of one missense mutation with a non-sense or bloodgroup O.
Mild deficiency of VWF in the range of 0.20 to 0.60 U/mL, with nor-
mal ratios of von Willebrand factor: ristocetine cofactor/antigen
VWF:RCo/Ag and VWF:collagen binding/antigen (VWF:CB/Ag), nor-
mal VWF multimers, and a completely normal response to desmo-
pressin acetate (DDAVP) with VWF level rising from below to above
1.00 U/mL are very likely cases of so-called pseudo-VWF defienciecy
in individuals with normal VWF protein and gene. Autosomal domi-
nant type 1 VWD variants are in fact type 2 variants caused by a het-
erozygous missense mutation in the VWF gene that produces a mu-
tant VWF protein that has a dominant effect on normal VWF protein
produced by the normal VWF allele with regard to the synthesis, pro-
cessing, storage, secretion, and/or proteolysis of VWF in endothelial
cells. A DDAVP challenge test clearly differentiates between domi-
nant type 1 VWD phenotype and dominant type 2 M VWD. 
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majority of type 2 von VWF defects (1). The clas-
sification of congenital von Willebrand disease
(VWD) as recommended by the VWF Scientific
Standardization Committee (VWF-SSC) of the
International Society on Thrombosis and
Haemostasis (ISTH) is based on laboratory phe-
notyping using the combination of factor VIII.C
and VWF: antigen (VWF:Ag) levels, ristocetine-
induced platelet aggregation (RIPA), and rather
insensitive tests for VWF: ristocetine cofactor
(VWF:RCo) and WVF muliteric pattern in a low-
resolution agarose gel (2). In the last decade,
accumulating data on the structure and function
relationship between laboratory phenotype and
expression VWF gene mutations, improved tools,
including VFW: collagen binding (VWF:CB)
assay and VWF multimeric analysis in high-reso-
lution agarose gels. The contribution of a desmo-
pressin acetate (DDAVP) challenge test has be-
come available for clinicians to better distinguish
and treat the various type 1 and type 2 VWDs. In
this study, we have evaluated the clinical fea-
tures, laboratory phenotypes, and genotypes of
severe autosomal recessive type 3 and 1 von
Willebrand disease (VWD), asymptomatic carri-
ers of a nonsense or missense mutation in the
VWF gene, bloodgroup O-related VWF deficien-
cy, and mild or moderate dominant type 1 VWD. 
Diagnosis and Classification of 
Type 1 and 3 VWD Patients
For the categorization of type 1 and 3 VWD
according to the SSC/ISTH 1993 the following
considerations have to be taken into account
1. Inherited VWD is caused by genetic muta-
tions at the VWF locus.
2. Type 1 VWD refers to partial quantitative
deficiency of VWF, type 2 VWD refers to qualita-
tive deficiency of VWF, and type 3 refers to vir-
tually complete deficiency of VWF.
3. Using better laboratory tools like high-resolu-
tion VWF multimeric analysis and more sensitive
functional assays like VWF collagen-binding assay
(VWF:CB), in view of new data on structure, func-
tion, and VWF gene defects, the “splitting” approach
is clearly superior in elucidating specific variants of
VWD and to differentiate type 1 from type 2 VWD.
4. Using molecular tools, the “spitting” ap-
proach will surely elucidate the differences be-
tween autosomal recessive type 3 and severe type
1 VWD, and will clarify much better the clinical
relevance and therapeutic implications of the dif-
ferent type 1 and type 2 VWD VWD patients.
A Simple Scoring System for 
Severity of Bleeding Symptoms
Experienced clinical coagulation-oriented
hematologists can easily assess the degree of an
acquired or congentital bleeding tendency by
using a simple scoring system for bleeding sever-
ity in patients with congenital VWD according to
Zhang et al (3) and Eikenboom et al (4):
Very mild: The patient has only one or two un-
clear minor bleeding symptoms without bleed-
ings after tooth extraction or surgery. 
Mild: The patient has one or two obvious mu-
cocutaneous symptoms, i.e, frequent episodes of
epistaxis, and/or prolonged or profuse menstru-
ation or frequent hematomas, which usually do
not require medical treatment or FVIII/VWF con-
centrate treatment. 
Moderate: A congenital bleeding tendency is
usually recognized since early childhood. The pa-
tient has recurrent mucocutaneous more than
two bleedings after tooth extraction, trauma, or
surgery and bleedings that needed medical treat-
ment and/or factor VIII/VWF (FVIII/VWF) con-
centrate transfusion because of abnormal bleed-
ing after an operation and/or trauma, or has
bleed for more than 24 hours after a tooth ex-
traction. In patients with congenital VWD, 
Severe: The patient has mucocutaneous bleed-
ing since early childhood plus, hemarthrosis,
muscle bleeding, and a need for prophylactic
treatment with FVIII/VWF concentrate that
refers to a pseudo-hemophilia bleeding type,
which is usually seen in type 3 VWD.
Laboratory Methods to Diagnose 
and Phenotype VWD
Bleeding times (BT) are usually measured ac-
cording to Ivy (5) or a standardized template de-
vice, mainly Simplate (6). BT measurements
have to be performed preferentially by experi-
enced technicians in reference coagulation labo-
ratories. Ivy and Simplate BT are recorded as
normal; prolonged between normal and 15, 20,
or 30 minutes; and strongly prolonged in excess
of 15, 20, or 30 minutes. Platelets are counted in
ethylene-diamine-tetra acid (EDTA) blood sam-
ples using a Platelet Analyzer. Platelet aggrega-
tion induced by collagen, adenosine diphosphate
(ADP), epinephrine, and ristocetine-induced
platelet aggregation (RIPA) is performed by
using various aggregometers according to stan-
dard procedures to exclude platelet function ab-
normalities.
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The PFA-100® (platelet function analyzer) is a
sensitive tool for the investigation of primary he-
mostasis. The PFA-100 uses whole blood flow
through a capillary device to mimic high shear-
stress conditions that occur in vivo in the end-ar-
terial microvasculature. The PFA-100 measures
the closure time when high-shear blood flows
through membrane cartridges coated with
platelet agonists and ceases as a result of platelet
adhesion and aggregation. There are two car-
tridge types available; both utulize a membrane
coated with collagen (C: fibrillar type 1 equine
tendon) in addition, one cartridge type is coated
with ADP (C/ADP) and the other with epineph-
rine (C/Epi). The two cartridges have slightly dif-
fering sensitivities to test variables and accord-
ingly yield slightly different normal ranges. Any
value of closure times above 250–300 seconds
(s) can be considered as maximally prolonged,
and values between the upper limit of normal
and 250 s as prolonged.
Both BT and PFA-100 are global test systems
used for screening of platelet and VWF disorders,
but they are not specific for, or predictive of, any
congenital or acquired platelet or VWF dysfunc-
tion. Once the diagnosis of VWD is made, BT and
PFA-100 can be used to estimate the severity of
bleeding tendency and for therapeutic monitor-
ing of bleedings.
Laboratory methods to diagnose von Wille-
brand disease include factor VIII: coagulant
(FVIII:C), VWF:Ag, VWF:RCo, VWF:CB, low- and
high-resolution VWF multemeric analysis, and
the result of a DDACP challenge test. Factor VIII
coagulant (FVIII:C) activity is assayed by means
of automatic coagulation machines using FVIII-
deficient plasma. VWF:Ag can be measured by a
variety of immunologic methods. The Laurel
rocked elecrophoresis has been replaced widely
by an enzyme-linked immunosorbent assay
(ELISA) (7,8). The VWF:RCo is determined ei-
ther by agglutination of fixed platelets measured
in an aggregometer or by a macroscopic slide
technique (8). The various VWF:RCo tests are
quantitative and allow identification of qualita-
tive VWF abnormalities because the ability of ris-
tocetine to influence the VWF interaction with
platelet membrane GPIbα depends on its multi-
merization. The VWF:RCo is rather insensitive to
measure levels lower than 0.10 U/mL owing to
an unacceptable degree of interassay and inter-
laboratory variability. The VWF:RCo and
VWF:CB assays are complementary to assess the
functional intactness or defects of the VWF in
type 1 and type 2 VWD, respectively. There is
also very good evidence that the VWF:CB assay
using equine collagen type 13 or a type I/III
(95%/5%) mixture (9–14) is much more sensi-
tive than the VWF:RCo for the measurement of
the hemostatic more potent high VWF multimers
present in plasma and FVIII/VWF concentrates.
The multimeric composition of VWF in most
studies is usually analyzed by sodium dodecyl
sulfate (SDS) agarose gel electrophoresis. A low-
resolution gel (0.6 to 1.2% agarose) has been
used as the first-line method because it clearly
differentiates between loss of the largest multi-
mers, the presence of supranormal multimers,
and normal samples but has limited power for
the relative loss of large multimers and to detect
the different banding patterns in various type 2
VWD patients. The medium-resolution gels (1.4
to 2.0% agarose), followed by quantitative eval-
uation by densitometry, which show the presence
or absence of all sizes of multimers (including
supranormal), together with the triplet structure
of individual multimers, are currently the basis
of proper laboratory phenotyping and classifica-
tion of type 1 and its differentiation from vari-
ous specific type 2 variants of VWD patients
(8,15,16).
Laboratory phenotyping of VWD is based on
measurements of FVIII:C, VWF:Ag, VWF:RCo,
VWF:CB, RIPA, and analysis of VWF multimeric
pattern to classify VWD according to established
criteria (2,8,16,17). VWD type 1 is a quantitative
VWF deficiency with equally decreased values of
all VWF parameters (<0.60 U/mL) and a normal
ratio of about 1 for VWF:RCo/Ag and
VWF:CB/Ag . VWD type 2 is a qualitative VWF
deficiency with normal, near-normal, or de-
creased levels for FVIII:C and VWF:Ag and much
lower values for VWF:RCo and VWF:CB with a
decreased ratio for both VWF:RCo/Ag and
VWF:CB/Ag (<0.60). Type 2 can easily be sub-
classified as 2A by a normal or decreased RIPA
and absence of large VWF multimers, as type 2B
by increased RIPA and absence of large VWF mul-
timers, and as 2M by decreased or zero RIPA and
presence of most of the large VWF multimers. 
By definition, the concentration in plasma of
FVIII:C and VWF:Ag is 1 U/mL (18). Conse-
quently the ratio FVIII:C/VWF:Ag in normal plas-
ma is by this definition 1 in all normal individu-
als with blood group O and non-O (18). In ho-
mozygous or double heterozygous type 2N VWD,
the ratio FVIII:C/VWF:Ag is decreased owing to a
FVIII:C binding defect of the VWF protein. The
ratio of FVIII:C to VWF:Ag on a molecular basis is
1:50, indicating that many potential FVIII:C
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binding sites on VWF:AG are free. As the VWF:Ag
is 50% of normal owing to decreased biosynthe-
sis in quantitative VWD type 1 heterozygous for
VWF null alleles, the ratio of FVIII:C/VWF:Ag
will increase to about 2 (18). As demonstrated
by Eikenboom et al (18), VWD type 1 heterozy-
gous for the VWF null allele indeed has a ratio of
2.06 for FVIII:C/VWF:Ag, and this ratio appears
to be dependent on the severity of the VWF:Ag
deficiency with ratios of 3.2, 1.96, and 1.46 at
VWF:Ag plasma levels of <30, between 30–60,
and above 60 U/mL (18). 
The protocol for DDAVP challenge testing can
be performed in the outpatient setting after in-
formed consent and counseling of the VWD pa-
tient by the responsible nurse and physician.
DDAVP 4 ug/mL is dissolved in sterile saline to a
total volume of 50 mL and infused over a 30-
minute period at a dose of 0.3 ug/kg. Measuring
the BT, FVIII:C, and all VWF parameters before
DDAVP (t=0), and at time points 0.25, 1, 2, 4, 6,
and 12 hours postinfusion of DDAVP, allows a
much better characterization of the various vari-
ants of type 1 and type 2 VWD based on the type
of response and calculation of the biological half-
life times of FVIII:C and the VWF parameters
(17). 
Autosomal Recessive Type 3 VWD and
Asymptomatic Heterozygous Type 1 “VWD”
The inheritance of VWD type 3 is autosomal
recessive (3,19,20). Patients with type 3 VWD
typically have strongly prolonged BT and aPTT;
FVIII:C levels between 1% and 9%; undetectable
VWF:Ag, VWF:Ag, and VWF:CB levels; and ab-
sence of RIPA (3,19–22). In 31 cases with type 3
VWD, (ages 2 to 80, median 15 years) described
by Schneppenheim et al (19), bleeding manifes-
tations were recorded as easy bruising and pro-
longed epistaxis in 31 (100%), spontaneous joint
bleedings in 23 (74%), muscle bleedings in seven
(22%), and gastrointestinal bleedings in three
(10%). As shown in Table 1, the bleeding mani-
festations and complications of childbirth have
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TABLE 1. Bleeding Manifestations and Complications of Childbirth in 385 Iranian Patients with Type 3 VWD22
Type 3 VWD Hemophilia A
FVIII:C 1% to 9% 1 %
VWF:Ag Undetectable Normal
VWF:RCo Undetectable Normal
RIPA Absent Normal
Bleeding time Strongly prolonged Normal
Number of patients (pts) 385 100
Age 2–72 Age matched
Type of bleedings: 
Spontaneous hemarthroses 37% 86%
Spontaneous muscle bleeding 52% 93%
Epistaxis >10 minutes 77% 20%
Oral cavity bleeding after tooth
Extraction or trauma or laceration
of tongue and lip 70% 64%
Menorrhagia usually controlled by
oral contraceptives in women 69% —
Gastrointestinal bleeding 20% 10%
Postoperative bleeding in 205, 
who underwent surgery 42% 36%
FVIII:C = Factor VIII coagulant deficiency, VWF:Ag = VWF: antigen, VWF:RCo = VWF: ristocetine cofactor, 
RIPA = ristocetine-induced platelet aggregation.
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been nicely evaluated by Lak et al (21) in 385
Iranian patients with autosomal recessive type 3
VWD as compared to age-matched severe hemo-
philia A. Among patients with type 3 VWD the
incidences of spontaneous hemarthroses (37%)
and muscle bleedings (52%) were lower, very
likely because FVIII:C levels were higher (1% to
9%) as compared to severe hemophilia A ( 1%).
Patients with type 3 VWD are homozygous or
compound heterozygous for two null alleles
(gene deletions, stop codons, frame shift muta-
tions, splice site mutations, and absence of mes-
senger RNA (mRNA) in the vast majority of re-
ported cases (3,19,20). Compound heterozygos-
ity for a null allele and a missence mutation or
homozygosity for a missence mutation are rare
in type 3 VWD (19).
The only objective and correct way to charac-
terize true type 1 VWF deficiency heterozygous
for the VWF null allele is to analyse the bleeding
manifestations and FVIII:C/VWF parameters in
obligate heterozygous parents of patients with
type 3 VWF. In the study of 27 patients with con-
genital type 1 VWF deficiency associated with
one null allele analyzed by Schneppenheim et al
(19), 22 were asymptomatic and only seven pre-
sented very mild bleeding, mainly bruising and
epistaxis. All, except one had normal BT. The
mean values for FVIII:C, VWF:Ag, and VWF:RCo
were 0.76, 0.39, and 0.39 U/mL, respectively,
with an increased FVIII:C/VWF:Ag ratio of 1.9
and a normal VWF:Rco/Ag ratio of 1 consistent
with true type 1 VWF deficiency (Table 2). In the
study of Zhang et al (3) including 25 patients
heterozygous for the VWF null allele and blood
group non-O, 12 had no history of bleeding and
13 presented with very mild bleedings (one or
two bleeding symptoms, mainly epistaxis, bruis-
es, and/or prolonged menstruations with no ab-
normal bleeding after tooth extraction). The
mean values for FVIII:C and VWF:Ag were 0.81
and 0.45, respectively, with an increased ratio
for FVIII:C/VWF:Ag of 1.8 (Table 2). In the same
study of Zhang et al (3) including 17 patients
heterozygous for the VWF null allele and blood
group A, eight had no bleeding history and 11
presented minor bleedings. The mean values for
FVIII:C and VWF:Ag were 0.74 and 0.32, respec-
tively, with an increased ratio for FVIII:C/
VWF:Ag of 2.3 (Table 2). In each of these two
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TABLE 2. Laboratory Phenotype and Clinical Symptoms in 69 Patients with True VWF Deficiency Type 1 Heterozygous for the VWF
Null Allele (Parents of Type III VWD)
Author Schneppenheim (19) Zhang (3) Zhang (2) Eikenboom (22)
Number of Patients 27 25 17 14 6
Blood group Not specified A O A O
FVIII:C, % 76 81 74 93 81
(range) (35–118) (37–121) (11–128) (69–138) (58–93)
VWF:Ag, % 39 45 32 61 52
(range) (27–68) (13–94) (12–70) (37–98) (40–66)
VWF:RCo, % 39 — — 56 53
(range) (16–57) — — (30–92) (39–68)
Ratio, FVIII:C/VWF:Ag, 1.9 1.8 2.3 1.52 1.56
Ratio, VWF:RCo/Ag 1 — — 1.66 1.52
(range) (0.55–1.92)
Mild bleedings,* n (%) 7 13 11 1 1
(26%) (52%) (65%) (7%) (17%)
*Mild bleeding is defined by one or two bleeding symptoms, mainly epistaxis, bruises, and/or prolonged menstruations without abnormal
bleeding after both extraction or surgery, hemarthros, or muscle bleeding. Abbreviations: See Table 1.
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studies (3,20), there was a wide range of values
from 0.11 to 1.28 U/mL for FVIII:C, from 12 to
0.94 for VWF:Ag, with ratios of FVIII:C/VWF:Ag
ranging from normal to increased above 2, indi-
cating the difficulty in distinguishing true con-
genital type 1 VWF deficiency from VWF defi-
ciency related to blood group O. In the study of
Schneppenheim (19), the VWF parameters in the
seven mildly symptomatic cases heterozygous for
the VWF allele ranged from 0.22 to 0.45 U/mL
for VWF:Ag and from 0.24 to 0.48 for VWF:RCo.
In the study of Zhang (3), 24 individuals het-
erozygous for the VWF allele (true type 1 VWF
deficiency) had VWF:Ag levels above 0.50 U/mL
in six and ranged from 0.13 to 0.45 U/mL in 18.
From these data it can be concluded that half of
the individuals with true VWF deficiency type 1
heterozygous for the VWF null allele are at risk
for very mild bleedings at VWF values between
0.20 to 0.50 U/mL, do have normal BT, and are
predicted to have a completely normal response
of FVIII:C and VWF parameters from below 0.50
to above 1.00 U/mL before and after DDAVP. 
We studied a consanguine family with type 3
VWD. The propositus was a young girl and pre-
sented with mucocutaneous bleeding and
hemarthroses of the ankle joints, FVIII:C 1%, and
absence of VWF due to homozygosity for the
non-sense splice site mutation IV7+1 G>A in in-
tron 7. Both parents were heterozygous for the
non-sense mutation and completely asympto-
matic with near-normal to normal values for
FVIII:C, VWF parameters, and normal ratios for
FVIII:C/VWF:Ag (Table 3). After DDAVP, the
FVIII:C levels rose to much higher levels as com-
pared to VWF:Ag, VWF:RCo, and VWF:CB levels,
resulting in high ratios above 3 for FVIII:C as
compared to each of the VWF parameters, but
VWF:Rco/Ag and VWF:CB/Ag were normal be-
fore and after DDAVP, consistent with true type 1
VWF deficiency (Table 3). This demonstrates
that an increased FVIII:C/VWF:Ag ratio after
DDAVP is typically diagnostic for true VWF defi-
ciency type 1 heterozygous for a null allele.
Autosomal Recessive Severe Type 1 VWD 
In 1975 Gralnick et al (23) described a large
family with three cases (two brothers, one sister)
of autosomal of recessive severe VWD featured
by strongly prolonged BT (>30 minutes), FVIII:C
levels of 8% to 16%, and undetectable VWF ac-
tivity (Table 4). The mother and another two
brothers and one sister had slightly prolonged BT
normal values for FVIII:C and FVIII:RA, subnor-
mal levels for VWF activity, and an abnormal pat-
tern in the cross immunoelectrophoresis (CIE)
using VWF antibodies, which is very suggestive
for a functional type 2 VWF defect of one allele
(Table 4). Such patients are carriers of a mis-
sense mutation and have mild von Willebrand
disease type 2. A sixth brother and a third sister
of this large family showed completely normal
values for FVIII:C, FVIII:RA, and VWF activity,
and a normal pattern on CIE. These data indicate
that in this family the three cases of severe re-
cessive VWD are very likely double heterozygous
for a missense mutation and a null allele, or dou-
ble heterozygous for two missense mutations. 
In 1979, Armitage and Rizza (24) described a
case with severe type VWD (BT 12 minutes,
FVIII:C 26%, and VWF:RCo <0.05) showing the
absence of a normal peak (= absence of normal
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TABLE 3. DDAVP Challenge Test VWD Type 1 Heterozygous for Null Allele
Antwerp Hemostasis Laboratory Marc van der Planken DDAVP:
Before After 1 2 3 4 6 Hours
FVIII:C 84 496 540 592 528 496
VWF:Ag 64 128 174 168 146 140
VWF:RCo 67 176 200 184 136 120
Budde Coagulation Laboratory Hamburg
VWF:CB 55 116 164 150 128 117
VWF:Ag 52 102 150 144 117 105
Abbreviations: See Table 1. DDAVP: desmopressin acetate.
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VWF protein) and the presence of an abnormal
peak (= presence of abnormal VWF protein on
VWF CEI (Table 4). The bleeding history of his
father’s family was negative, but his sister, moth-
er, and another four members of his mother’s
family had an autosomal dominant mild bleed-
ing history with partial penetrance of easy bruis-
ing epistaxis, slightly prolonged BT, and a double
peak on VWF CEI indicating the presence of nor-
mal and abnormal VWF protein, but the values
for FVIII:C, factor VIII: related antigen
(FVIII:RA), and VWF:RCo were normal. These
data of abnormal VWF protein in the propositus
with severe VWD and the presence of a double
VWF peak with autosomal dominant inheritance
in family members is consistent with homozy-
gosity for a missense mutation or double het-
erozygosity for a missense/null allele of the
propositus for a functional VWF defect. The dou-
ble VWF peak on CIE refers to heterozygosity for
a missense mutation in the mildly symptomatic
maternal family members (Table 4).
Compound heterozygosity for a null allele and
a missence mutation or homozygosity for a
missence mutation are rare in type 3 VWD
(3,19,20), but are common and frequently traced
in patients with severe autosomal recessive type
1 VWD (22). Patients with autosomal recessive
severe type 1 VWD who are ccompound het-
erozygous for a null allele and a missense muta-
tion, or homozygous or double heterozygous for
a missense mutation, have detectable but very
low VWF levels (Table 5). 
Homozygotes for the missense mutations
W377C (exon Schneppenheim et al (19) and for
R273W (exon 7, Allen et al (25)) in propeptide
D1 domain have been described to be associated
with autosomal recessive severe type 1 or even
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TABLE 4. Autosomal Recessive Severe Type 1 VWD in Two Large Families with Autosomal Dominant Trait of Asymptomatic 
or Mild Type 2 VWD
Gralnick et al, 1975 (23) BT FVIII:C FVIII:RA VWF Activity CIE VWF Protein
Propositus (male) >30 0.09 0 0 No VWF protein
Brother 1 >30 0.10 0 0 No VWF protein
Sister 1 >30 0.16 0 0 No VWF protein
Mother* 16-20 0.90 – 0.10 Abn VWF protein
Brother 2* 9-15 1.30 – 0.42 Abn VWF protein
Brother 3* 11 1.10 – 0.42 Abn VWF protein
Sister 2* 8 1.15 – 0.56 Abn VWF protein
Normal <8 >0.60 >0.60 >0.60 Normal VWF peak
* = Asymptomatic, but slightly prolonged BT and abnormal (abn) VWF protein on CIE.
Armitage and Rizza, 1979 (24) BT FVIII:C VWF:RCo Bleeding CIE VWF Protein 
Propositus (male) 12 0.26 <0.05 Moderate Normal peak absent
Abn peak present
Sister 5 1.04 Normal None Double VWF peak
Mother 6 0.86 Normal Mild Double VWF peak
Maternal uncle 5 1.01 Normal Mild/moderate Double VWF peak
Maternal aunt 3 0.62 Normal Mild/moderate Double VWF peak
Four nonaffected maternal 
family members <3 Normal Normal None Normal VWF peak
Father and paternal
family members <3 — — All asymptomatic Not tested
Abn = abnormal, BT = bleeding time, CIE = cross immunoelectrophoresis, FVIII:C = factor VIII coagulant deficiency, FVIII:RA = factor VIII
related antigen, VWF:RCo = VWF ristocetine cofactor.
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type 3 VWD. Reported cases of severe recessive
type 1 VWD are in fact autosomal recessive se-
vere type 2 VWD as demonstrated by VWF mul-
timer analysis (25–29). The multimeric pattern
of homozygous R273W clearly showed the ab-
sence of high-molecular-weight multimers and a
pronounced monomeric band consistent with
type 2A or 2E VWD (25). Homozygosity for the
missense mutation C2364F in a family and dou-
ble heterozygosity for C2364F/null in three
families have been reported to be associated
with severe type 1 VWD featured by FVIII:C lev-
els of 12 to 32 U.L, very low but detectable
VWF:Ag, and undetectable VWF:RCo (Table 5)
(22). In some of these patients with severe type
1 VWD, FVIII:C, VWF:Ag, and VWF:RCo
reached values of >0.50, 0.11, and 0.09 U/L,
respectively, after DDAVP (26). C2364F het-
erozygous carriers were asymptomatic, had nor-
mal or slightly prolonged BT, subnormal values
for VWG:Ag and VWF:RCo with a normal
VWF:RCO/Ag ratio, and a normal VWF multi-
meric pattern in a low 0.8% or 0.9% agarose
resolution gel (27). However, analysis of VWF
in plasma from cases with severe autosomal re-
cessive VWD homozygous for a missense muta-
tion C2362F or compound C2362F/null (exon
42 of the B1-3 domain), as well as heterozygous
carrier of C2364F, all showed a heightened pro-
teolytic pattern with marked increase of 176
and 140 kDA degradation products consistent
with type 2A VWD (Table 5) (27). Castaman et
al (28) described another case of severe auto-
somal recessive type 1 VWD double heterozy-
gous for two missense mutations C2364/
splice site (Table 5). 
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TABLE 5. Reports of Autosomal Recessive Severe Type 1 VWD Caused by Homozygous Missense Mutations or Compound
Missense/Null Mutations Showed a Type 2 VWD on Multimeric Analysis of VWF Protein
Author/Mutation F/M, Age BT VIII:C VWF:Ag VWF:RCo VWF:CB RIPA VWF:MM
Schneppenheim, 1994 (19)
W377C/W377C 2 yr >20 0.02 0.03 0.03 — — nt
Eikenboom, 1998 (22), 
Castaman, 2000 (27)
C2362F/C2362F F >30 0.19/0.44 0.02 <0.03 — — 2A
C2362F/splice site M >30 0.01/0.28 0.01 <0.03 — — 2A
C2362F/R2535*null F >30 0.11/0.30 0.01 <0.03 — — 2A
C2362F/737insC F >30 0.08/0.21 0.02 >0.03 — — 2A
C2671Y/del null F >30 0.10/0.19 0.03 <0.03 — — 2A
4699/? M 15 >20 0.25/0.37 0.11 <0.03 — —
C2671Y/W2193R M >30 0.18/0.33 0.6 <0.03 — —
(Gene conversion)
Castaman, 2002 (28)
C2362F/splice site M 3 yr >15 0.18 0.05 <0.03 — — N low
0.21 0.07 0.07 resolution
Schneppenheim, 2001 (29)
C2754W/C2754W >20 0.12 <0.05 <0.05 — — 2D
Allen, 2000 (25)
R273W/R273W Boy 15 0.20 0.06 0.06 — — 2A or 2E
R273W/R273W Boy 15 0.33 0.09 0.04 — — 2A or 2E
R273W/R273W Boy >20 0.09 <0.01 <0.01 — — —
Abbreviations: See Table 1. VWF:CB = VWF: collagen binding, VWF:MM = VWF multimers.
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Homozygosity for a dimerization defect in the
C terminal domain of the VWF gene C2754W
caused type 3 VWD with undetectable VWF:Ag,
RCo, and CB (Schneppenheim et al) (29).
Repeated VWF multimeric analysis of the pa-
tient’s platelet could detect only low-molecular-
weight mutimers, and further analysis revealed
intervening bands between individual bands con-
sistent with type 2D VWD. Eikenboom (22) de-
scribed a case of autosomal recessive type 1 VWD
due to double heterozygosity for the mutation
C2671Y in exon 49 of the dimerization region of
the VWF gene for which analysis of the VWF
multimeric pattern was not performed. 
Finally, clinicians have to be aware that type
2N VWD may present with normal BT and equal-
ly decreased VWF:Ag and VWF:RCo simulating re-
cessive type 1 VWD, but FVIII:C is much lower as
compared to VWF:Ag owing to an FVIII binding
defect in the D’domain of the VWF protein (4).
Bloodgroup O-Related VWF Deficiency 
and Asymptomatic Carriers of a VWF 
Missense Mutation
ABO blood group is a well-known significant
determinant of plasma VWF concentration. In
the study of Gill et al (30), 456 normal individu-
als with blood group O had the lowest VWF:Ag
levels (mean 0.75 U/mL with an ±SD of
0.35–1.57), followed by blood group A (mean
1.06 ±2SD 0.48–2.33), and then blood groups B
and AB with completely normal VWF level.
About one third of individuals with blood group
O, only a few with blood group A, and hardly any
with blood groups B and AB had VWF levels
below 0.60 U/mL. Of 114 patients diagnosed as
having type 1 VWD in the study of Gill et al (31),
blood group O was found in 77%, blood group A
in 18%, B in 4%, and AB in 0%, whereas the fre-
quency of these blood groups in the normal pop-
ulation was significantly different: 45%, 45%,
7%, and 3%, respectively. These data strongly in-
dicate that a large proportion of patients diag-
nosed as having very mild or mild type 1 VWD
have decreased concentration of structurally nor-
mal VWF protein in the range of 0.25 to 0.60
U/mL with normal FVIII:C/VWF:Ag and
VWF:RCo/Ag ratios just on the basis of congeni-
tally determined blood group O and a normal
wild-type sequence of the vWF gene (pseudo-
VWF deficiency) (30,31). Sadler (31) calculated
that most diagnoses of VWD type 1 are false pos-
itive: 25% of the individuals in the population
have one or two bleeding symptoms (mild bleed-
ing), and 2.5% of the general population have
low plasma VWF concentrations. Thus 0.25 ∞
0.025 = 0.6% individuals of the general popula-
tion have by chance low VWF levels and mild
bleeding symptoms just by chance. If a positive
family history of mild bleedings is taken into ac-
count, then still 0.04% of individuals have by
chance the combination of mild bleeding symp-
toms and low VWF levels. Heterozygous type 1
deficiency (carriers of VWF null allele) and pseu-
do-VWF deficiency can cause very mild or mild
bleedings, but such very mild and mild bleedings
may have many causes, are very common, and
are not specific (31). A moderate and persistent
bleeding tendency (of mucocutaneous type in the
absence of petechiae) since early childhood is
very suspicious and rather specific for a clinically
relevant congenital VWF defect (17).
Coughlan et al (32) evaluated the presence of
VWF null alleles in a cohort of 36 unrelated pa-
tients with type 1 VWD according to SSC recom-
mendations of the ISTH and in a group of 82
control persons. VWF null alleles were not found
in their type 1 VWD (and therefore labeled as
pseudo-VWF deficiency) and also not in the con-
trol population. The frequency of bloodgroup O
in their type 1 patients was 72%, which is high-
er than the 43% in their control population. Of
62 parents of type 3 patients with a documented
null allele, 23 (37%) had bloodgroup O (Table
2). These observations reflect the complexity un-
derlying the expression of a laboratory pheno-
type type 1 VWD and imply the involvement of
asymptomatic heterozygous missense mutations
in the VWF gene, genetically determined factors
like blood group O, and other congenital or ac-
quired, still unknown, factors as well. In this con-
text two recent studies confirmed this view by
the observation that the missense mutation
(polymorphism) Y1584C in exon 26 of the VWF
gene was enriched in symptomatic VWD type 1
(14%), and the majority of these Y1584C het-
erozygotes (about 90%) were of bloodgroup O
(33,34). Bleeding manifestation in propositi in
nine type 1 families with the Y1584 mutation
and bloodgroup O were mild in two and mild to
moderate seven (33). The laboratory phenotype
of probands with the combination of C1584C and
bloodgroup O was typically type 1 VWD with
mean values of FVIII:C 0.54 (0.11 to 1.01),
VWF:Ag 0.40 (0.24 to 0.50), and VWF:RCo 0.36
(0.29 to 0.46) (33). Heterozygosity for the mis-
sense mutation Y1584C was found in 2 of 200
random controls by Bowen (34), and in one
asymptomatic case (VWF:Ag 0.50 U/mL) among
100 healthy controls by O’Brien (33). 
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Pseudo-VWD
We prospectively studied the probands of 24
unrelated families diagnosed as having so-called
mild VWD type 1. Bleeding manifestations were
mild and the BT usually normal on repeated oc-
casions. The levels for VWF:Ag, VWF:RCo, and
VWF:CB were between 0.20 to 0.60 U/mL with
normal ratios for VWF:RCo/Ag (Fig. 1) (17).
FVIII:C levels were somewhat higher as com-
pared to VWF:Ag with a FVIII:C/VWF:Ag ratio
of 1.48 (range 0.8–2.2). VWF:Ag levels of 0.20
and 0.60 before DDAVP reached high peak val-
ues all above 1.0 U/mL with a mean of 2.16
U/mL (range 1.15 to 3.18 U/mL) after DDAVP
(Fig. 2) (17). After DDAVP the ratios of
VWF:RCo/Ag remained normal (0.97, range
0.65–1.34), but the ratio of VWF:CB/Ag signif-
icantly increased to 1.60 (range 1.03–2.28), in-
dicating the release of unusually high VWF mul-
timers immediately after DDAVP (Fig. 1) (17).
Interestingly, the ratio FVIII:C/VWF:Ag re-
mained normal or corrected to normal after
DDAVP in nearly all probands (Fig. 1), which
(based on the analysis above) is very suggestive
for a pseudo-VWF deficiency rather than a ge-
netically determined true type 1 VWF deficien-
cy (17,31). The values for FVIII:C and VWF pa-
rameters remained in the low normal range for
24 hours after DDAVP infusion (Fig. 2). There
were only a few probands showing typical fea-
tures suspicious for true type 1 VWD before and
after DDAVP with increased FVIII:C/VWF:Ag ra-
tios of about 2 and normal VWF:RCo/Ag ratios
(Fig. 3).
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FIG. 1. VWF parameters before and within 15 minutes after intravenous DDAVP in 26 patients with mild VWF
deficiency showing normal responses of VWF:Ag, and VWF:RCo and supernormal response of VWF:CB (mainly
pseudo-VWD, see Fig. 2).
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Autosomal Dominant Type 1 VWD
In our cohort of five VWD patients with severe
type 1 VWD (17), we found three probands from
different families with severe type I VWD (vWF
parameters <0.20 U/mL), who had 1) a mild to
moderate bleeding history since childhood, 2) a
normal RIPA, 3) a normal or slightly prolonged
Ivy BT, 4) a normal VWF multimeric pattern but
a decreased response of VWF parameters to
DDAVP suggesting a secretion defect of VWF
from endothelial cells (Fig. 4). In these three
probands, the ratio of FVIII:C/VWF:Ag was
above 3 before and after DDAVP (Table 6),
which is very suggestive for a decreased synthe-
sis or secretion defect due to a not yet defined
VWF missense mutation. We propose to label this
category as autosomal dominant moderate VWD
type 1 due to a secretion defect (Table 6).
Eikenboom et al (35) demonstrated that the clas-
sical autosomal dominant type 1 VWD with high
penetration of moderate bleeding symptoms was
caused by a heterozygous missense mutation
Cys367 ∅ Phe (C1130F) in one and Cys386 ∅ Arg
(C1149R) in another family. These two missense
mutations are located in the D3’ domain and in-
terfere with the normal VWF subunits coded by
the normal VWF allele, causing a defective intra-
cellular multimerization and degradation of
VWF, and leading to a secretion defect of the
VWF by endothelial cells (35,36). The autosomal
dominant severe type 1 VWD (C1130F) is fea-
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FIG. 2. Normal responses to DDVAP of FVIII:C and VWF parameters in 3 patients with mild VWF deficiency consistent with pseudo-
VWD.
FIG. 3. Good response to DDAVP in a case of mild
type 1 VWD showing an increased ratio of
FVIII:C/VWF:Ag and a normal ratio of VWF:RCo/Ag
before and after DDAVP.
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tured by low WF levels of <0.20 U/mL and the
presence of all sizes of VWF multimers, and an
increased FVIII:C/VWF:Ag ratio of 2.0 to 2.3 con-
sistent with a “synthesis ∅ secretion” defect of
VWF deficiency type 1 (Table 6). A similar dom-
inant-negative mechanism of intracellular reten-
tion and degradation of VWF caused by het-
erodimerization of mutant and normal VWF sub-
units in the endoplasmatic reticulum followed by
proteosomal degradation in the cytoplasm has
been described for the C1149R mutation, but the
laboratory features of this autosomal dominat
type 1 mutant are not reported (36). Castaman
et al (37) screened 24 unrelated Italian patients
with autosomal dominant type 1 VWD for the
C1149R and C1130F mutations. None of the pa-
tients had the C1149R mutations and three ap-
parently unrelated patients showed the presence
of the C1130F mutations (formerly reported as
C367F) and typical features of severe dominant
type 1 VWD with VWF values below 15 U/dL and
increased FVIII:C/VWF:Ag ratios (Table 6).
Casana et al (38) reported the association of
dominant mild type 1 VWD with increased
FVIII:C/VWF:Ag ratios in seven members of one
family with heterozygosity of T1156M in the D3
domain of the VWF gene. Federici et al (39) de-
scribed a family (grandfather, mother, and new-
born daughter) with severe type 1 VWD, subtype
‘plasma low-platelet low,’ that could be explained
by decreased synthesis of VWF in endothelial cells
of cultured endothelial cells isolated from the um-
bilical vein of the newborn daughter. This family
can now readily be reclassified as having autoso-
mal dominant severe type 1 VWD (Table 6).
Diagnostic Differentiation Between Dominant
Type 1 Versus 2M or Variant Type 2A VWD
In 1985 Mannucci et al (40) described 17 pa-
tients from 13 kindreds with pronounced VWD
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FIG. 4. Normal response of FVIII:C and decreased response of VWF parameters to DDAVP in three cases (one
woman, left, and one brother and sister, middle and right, respectively) showing an increased ratio of FVIII:C/VWF:Ag
and a normal VWF:RCo/Ag ratio before and after DDAVP consistent with dominant type 1 VWD.
 at Erasmus Univ Rotterdam on August 14, 2015cat.sagepub.comDownloaded from 
with VWF values below 0.20 in all them and
identified three subtypes in this cohort accord-
ing to the content of VWF in patient platelets, in-
dicated as platelet normal, platelet discordant,
and platelet low. In this study, type 1 platelet
normal VWD was characterized by normal con-
tent of platelet VWF, a normal response to
DDAVP, and normal BT before and after DDAVP,
followed by normal half-life times of VWF para-
meters. Type 1 platelet discordant VWD was
characterized by the absence of most of the large
VWF multimers, abnormal VWF:Ag content and
deficient VWF:RCo in platelets, a discrepant re-
sponse to DDAVP with a good response of FVIII:C
and VWF:Ag, a poor response of VWF:RCo, and
only a transient and partial correction of the
strongly prolonged BT. This category has been
reclassified by Sadler (31) as a variant of type
2A. The six patients with very severe type 1 VWD
platelet low were featured by a strongly pro-
longed BT, a normal pattern of VWF multimers
in the densimetric scans of a 1.4% agarose gel,
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TABLE 6. Laboratory Data on 6 Families with Autosomal Dominant Type 1 VWD 
F vWF: Ratio Ratio
VIIIc Ag Rcof CBA vWF- VIII:C/ Response vWF
Author BT u/mL u/mL u/mL u/mL CBA/Ag VWF:Ag RIPA to DDAVP MM
Michiels et al, 2002 (17)
Family 1 N 19 9 <10 12 1.3 2.1 N Decreased N
‘type 1’
Family 2 ↑ 56 17 16 13 0.8 3.3 N Decreased N
‘type 1’
Family 3 
Mother ↑ 67 19 14 21 1.1 3.5 N Decreased N
‘type 1’
Daughter ↑ 65 19 23 16 0.9 3.4 N Decreased N
‘type 1’
Brother ↑ 82 21 17 27 1.3 3.9 N Decreased N
‘type 1’
Eikenboom et al, 1996 (35) RCo/Ag
Family 4
Father ↑ 21 10 <20 — — 2.1 — — N
Son ↑ 22 11 <20 — — 2.0 — — N
Daughter ↑ 35 15 <20 — — 2.3 — — N
Federici et al, 1993 (39)
Grandfather ↑ 35 10 7 — 0.7 3.5 — — N
Mother ↑ 28 8 6 — 0.75 3.5 — Decreased N
Daughter ↑ 24 10 6 — 0.60 2.4 — — N
Dominant type 1 VWD in 7 members of one family associated with T1156M in the D3 domain of the VWF gene
Casana et al, 2001 (38)
II:1 nr 0.80 0.39 0.27 nt 0.7 2.1 — Good N
II:2 nr 0.69 0.37 0.29 nt 0.78 1.9 — N
III:4 nr 0.62 0.28 0.17 nt 0.60 2.2 — N
III:8 nr 0.59 0.27 0.17 nt 0.62 2.2 — N
IV:1 nr 0.68 0.36 0.31 nt 0.86 2.2 — N
IV:2 nr 0.70 0.35 0.20 nt 0.57 2.0 — N
↑ = prolonged, N= normal, decr = decreased, — = not tested.
N = normal VWF multimers in low-resolution agarose gel.
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and very low plasma VWF levels in whom
platelet VWF:Ag and VWF:RCo were equally low
(“type 1 platelet low”). After DDAVP the BTs
only partially corrected for a few hours and plas-
ma VWF:Ag remained low (less than 0.50
U/mL), VWF:RCo remained very low (less than
0.25 U/mL) owing to defective production of
VWF in cellular compartments, whereas FVIII:C
levels increased to values between 0.70 to 1.30
U/mL (Fig. 5, Mannucci et al (40)) consistent
with a severe secretion defect type 1 (1 SD) or
autosomal recessive type 1. 
Cattaneo et al (41) evaluated the response to
DDAVP in nine patients with type 1 platelet nor-
mal, six patients with platelet low, and three pa-
tients with platelet discordant. The nine VWD pa-
tients with VWD type 1 platelet normal was fea-
tured by mild disease, mean values of 41
(19–64) for VWF:Ag and 43 (21–54) for
VWF:RCo, and a completely normal response of
VWF parameters to DDAVP followed by normal
half-life times consistent with mild type 1 VWD
or pseudo-VWD (Fig. 5). The six vWD patients
with type 1 platelet low had low values of 16
(1–38) for VWF:Ag and 5 (5–32) forVWF:RCo
and a poor response to DDAVP for both WVF;Ag
and VWF:RCo (Fig. 5) consistent with a type of
secretion defect. The three VWD patients with
type 1 platelet discordant had mean values of 44
(11–81) for VWF:Ag and 5 (5–33) for VWF:RCo,
but the response to DDAVP was good for VWF:Ag
and poor for VWF:RCo (Fig. 5) and therefore
consistent with 2M or 2A variant (17,31). In this
cohort of VWD patients, Simplate BT was pro-
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FIG. 5. Responses to DDAVP in type 1 DDAVP according to the classification
of Mannucci et al (40) and Cattaneo et al (46). Left: Normal response to
DDAVP of both VWF:Ag and VWF:RCo in mild type 1 VWD “platelet normal”
consistent with either pseudo-VWD or mild type 1 VWD. Middle: Poor response
to DDAVP of both VWF:Ag and VWF:RCo in type 1 VWD “platelet low”
consistent with recessive type 1 or 2A-like VWD. Right: good response of
VWF:Ag and poor response of VWF:RCo to DDAVP in type 1 VWD “platelet
discordant” consistent with type 2M VWD.
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longed in VWD type 1 platelet low, but normal in
most VWD patients with platelet normal, and dis-
cordant. The PFA-100 closure times (PCT) was
normal in five of the nine patients with VWD
type platelet normal and prolonged in all VWD
patients with type 1 platelet low and discordant.
Treatment with DDAVP corrected the PCT to nor-
mal in patients with VWD type 1 platelet normal,
but not in platelet low and discordant. 
Fressinaud et al (42) evaluated BT (Simplate)
and PCT (PFA-100) in 36 patients with type 1
VWD. VWD type 1 was defined by a quantitative
deficiency of both VWF:RCo and VWF:Ag levels
below 0.40 U/mL without taking into account
the results of RIPA and disregarding the
VWF:RCo/Ag ratios as the first steps to differen-
tiate type 1 and type 2 VWD. In this study, 14
patients (cases 1 to 14) had very mild type 1
VWD featured by VWF:RCo levels between 0.28
and 0.39, normal VWF:RCo/Ag ratios, normal BT
in 10, and prolonged PCT not exceeding 250 s in
most of them. Thirteen VWD patients (cases 23
to 36) had low VWF:RCo levels between 5 and
0.16 U/mL, prolonged PCT (>250 s), and pro-
longed BT in seven of them. Eight of these 13
VWD patients had decreased ratios for VWF:
RCo/Ag consistent with a variant of type 2 VWD.
Six patients (cases 16 to 22) had values of
VWF:RCo between 0.22 and 0.27 with normal
VWF:RCo/Ag ratios, prolonged BT in five, and
PCT above 250 s in most of them. Eight patients
(cases 29 to 36) had severe VWD with values for
VWF:RCo of 0.10 U/mL or less, and at this low
level it is rather difficult to differentiate between
true type 1, type 2M, or a variant of type 2A. 
In our cohort of five probands with severe type
1 VWD (17), we found two probands with severe
type 1 VWD and decreased RIPA, that could be
classified as VWD type 2M because of a very
characteristic response to DDAVP (Fig. 6) (43).
The typical laboratory features in our VWD type
2 M patients are 1) “severe type 1,” 2) decreased
RIPA in the presence of a normal or near-normal
VWF multmeric pattern in a low-resolution
agarose gel, 3) a poor response to DDAVP of
VWF:RCo, and 4) a good response of both
VWF:CB and VWF:Ag to DDAVP, which is con-
sistent with the presence of all VWF multimers
and can explain the slightly normal to slightly
prolonged Ivy BTs before and after DDAVP (Fig.
6) (17). In a study performed in 317 patients
previously registered as type 1 VWD, 30 patients
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FIG. 6. Poor response of VWF:RCo and good responses of FVIII:C, VWF:AG and VWF:CB
to intravenous DDAVP in two cases with type 2M VWD.
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from 17 unrelated families with discrepant
VWF:RCo/Ag ratios of plasma and normal VWF
multimers could be reclassified as type 2M (44).
RIPA assay was previously performed in 26 of 30
2M patients and an absent or decreased respon-
siveness to ristocetin with minor aggregation at
1.5 mg/mL was found in all cases (44). This sim-
ply may mean that all cases of severe type 1
CvWD with a normal or near-normal VWF multi-
meric pattern, a decreased or absent RIPA, and a
decreased VWF:RCO/Ag ratio can currently be
reclassified as 2M VWD. However, the diagnostic
differentiation of dominant severe type 1 VWD
versus type 2 M and 2 U remains a challenge that
will be addressed in our manuscript on classifi-
cation of type 2 VWD (43). 
Autosomal Dominant VWD Type 1 Vicenza
Congenital VWD Vicenza clearly differs from
2M and 2U. VWD Vicenza is featured by equally
low levels of FVIII:C, VWF:Ag, and VWF:RCo;
usually normal RIPA; a normal or slightly pro-
longed BT; and the presence of unusually large
vWF multimers in plasma (44,45). Cattaneo et
al (46) evaluated the Simplate BT, PFA-100 clo-
sure times (PCT), VWF parameters, and the re-
sponse to DDAVP in five patients with VWD
Vicenza. The values for VWF:Ag and VWF:RCo
were very low (2–9) and 5 (5–6), respectively,
in VWD Vicenza. Simplate BT was normal and
PFA-100 closure times (PCT) were prolonged be-
fore and normalized after DDAVP in VWD
Vicenza. The response to DDAVP in several cases
of VWD Vicenza in the study of Casonato et al
(45) and Cattaneo et al (46) was good for
FVIII:C, VWF:Ag, and VWF:RCo, which was fol-
lowed by unexplained very short half-life times
of less than a few hours for FVIII:C and all VWF
parameters consistent with a laboratory type 1
phenotype. The ratios for FVIII:C/VWF:Ag and
VWF:RCo/Ag and VWF:CB/Ag remained normal
before and after DDAVP (17,45,46). Schnep-
penheim et al (47) analyzed the complete cod-
ing region (exons 2 to 52) and adjacent intron
sequences of the VWF gene in 23 patients with
VWD Vicenza: three patients from the two Italian
families originally described in Vicenza (45), 13
patients from five additional Italian families, and
seven patients from three German families with
VWD Vicenza (48). In six patients from two
German families, who had significantly higher
VWF:Ag and VWF:RCo levels (between 10–221
U/dL) and much higher FVIII:C levels, no genet-
ic defect could be detected. In the other 17 pa-
tients with significantly lower VWF values
(below 10 U/dl except in two) including all
Italian families, a single mutation R1205H in the
D3 (multimerization) domain was found as the
probable cause of VWD type Vicenza (47). The
causative relationship between the mutation
R1205H and the VWD type Vicenza is still un-
clear. Decreased proteolysis due to relative resis-
tance to the VWF-specific protease is unlikely
since the triplet structure of the individual VWF
Vicenza multimers as the result of proteolysis is
normal. Multimeric analysis of plasma and
platelet VWF of patients with the mutant VWF
Vicenza clearly show dense bands of the ul-
tralarge and large multimers and a very dense
band of degraded VWF with relative faint bands
of intermediated and low multimers as compared
to normal VWF mutimeric pattern (44). This dif-
ference can readily be explained by the rapid and
complete degradation of the FVIII/VWF complex
of the mutant VWF Vicenza within a few hours,
but the absence of increased triplet structure due
to rapid proteolysis, as seen in types 2A and 2B,
clearly indicates that the mechanism of rapid
degradation of VWF Vicenza multimers is differ-
ent and not caused by proteolysis. After DDAVP,
FVIII:C and VWF parameters reach normal val-
ues indicating normal synthesis, but the
FVIII/VWF complex of the mutant VWF Vicenza
is rapidly cleared, whereas in types 2A and 2B
VWD there is a normal release of FVIII:C and
VWF:Ag after DDAVP with normal half-life times
for FVIII:C and VWF:Ag and very short half-life
times for VWF:RCo owing to proteolysis of large
VWF multimers (17). 
CONCLUSIONS
Classification of type 1 and type 3 VWD based
on clinical, laboratory, and molecular features is
shown in Table 7. Recessive type 3 VWD is
caused by homozygous or double heterozygous
non-sense mutations in the VWF gene (null alle-
les). The complete absence of VWF is compatible
with life. The loss of VWF results in FVIII:C defi-
ciency ranging from 1% to 9%. Type 3 VWD is
easy to diagnose by the combination of a strong-
ly prolonged BT, absence of RIPA, absence of
VWF, and FVIII:C deficiency and is associated
since early childhood with a pronounced ten-
dency to mucocutaneous and musculoskeletal
bleedings. Carriers of one null allele are usually
asymptomatic at VWF levels between 15% and
90% of normal. Bloodgroup O has a minor influ-
ence (-10%) on FVIII:C and VWF levels.
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Recessive type 1 VWD differs from type 3
VWD by the presence of detectable VWF:Ag and
FVIII:C levels between 0.09 to 0.40 U/mL.
Recessive severe type 1 VWD is caused by ho-
mozygous or double heterozygous missense mu-
tation in the VWF gene resulting in the reduced
production of abnormal VWF protein. Patients
with recessive type 1 VWD indeed show an ab-
normal VWF multimeric pattern in plasma
and/or platelets consistent with severe type 2
VWD. Carriers of a missense mutation may have
mild bleeding and mild VWF deficiency and can
be diagnosed by a double VWF peak on CIE.
There will be cases of mild and moderate reces-
sive laboratory phenotype type 1 VWD due to
double heterozygosity of two identical or differ-
ent missense or one missense and one non-sense
mutation and such cases are in fact variants of
type 2 VWD. 
Bloodgroup O itself is a cause of congenital
VWF deficiency (30,31). Recently, it has become
evident that the combination of a missense mu-
tation Y1584C and bloodgroup O is associated
with symptomatic mild VWD (32,33). Mild defi-
ciency of VWF in the range of 0.20 to 0.60 U/mL,
with normal ratios of VWF:RCo/Ag and
VWF:CB/Ag, normal VWF multimers, and a com-
pletely normal response to DDAVP with VWF
level rising from below to above 1.00 U/mL are
very likely cases of pseudo-VWD in individuals
with normal VWF protein and gene. Autosomal
dominat type 1 VWD variants are in fact type 2
variants caused by a heterozygous missense mu-
tation in the VWF gene that produces a mutant
VWF protein, which has a dominant effect on
normal VWF with regard to the synthesis, pro-
cessing, storage, secretion, and/or proteolysis of
VWF in endothelial cells. 
VWD Vicenza represents a specific example
with a normal secretion of ultralarge VWF multi-
mers followed by a fivefold more rapid clearance
of the FVIII-VWF complex, resulting in FVIII:C
and VWF levels below 15 U/mL and therefore to
be categorized as type 1 VWD (49). 
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TABLE 7. The Antwerp Classification and Characterization of Quantitative Type 1 and Type 3 von Willebrand Diseases (VWD)
VWF (%) Bleeding VWF Gene
Category VWD BT FVIII:C (%) Ag RCo RIPA Type Mutation
Severe type 3 ↑↑↑ 1–9 Zero Zero Zero Severe Double 
Recessive Hemophilia Non-sense
Severe type 1 ↑↑↑ 9–40 1–10 0–6 Zero Moderate Double
Recessive Severe Missense
Bloodgroup O (30–32) N 35–150 35–150 35–150 N Asymp None
(Pseudo-VWD) Very mild
Carrier type 3 N↑ 30–140 15–90 15–90 N Asymp Single 
Minor influence (-10%) Very mild Non-sense
of bloodgroup O (null allele)
Carrier type 1 N N N N N Asymp Single
(polymorphism) Missense 
Mild type 1 N↑ 20–80 20–50 20–50 N Mild Mis/Non-sense
Recessive or or Y1584C/
Variable penetrance and multigenetic background Bloodgroup O 
(19,50)
Dominant type 1 N↑ 20–80 10–40 0–30 N Mild Single
Secretion defect ↑/↑↑ 5–20 5–20 5–20 Moderate Missense
Dominant Type 1
Vicenza N/↑ <15 <15 <15 Moderate SingleR1205H
Missense
Designed by Michiels, 2004.
N = normal, asymp = asymptomatic.
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